{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-034761","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.670038+00:00","generated_at":"2026-06-13T02:22:16.943691+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kezar Life Sciences reprices executive stock options to $2.28","bullets":["Compensation Committee approved repricing of 2018 Plan options to $2.28/share, the July 24 closing price.","CEO John Fowler: 2,655,000 options repriced from $3.29-$22.85; CFO Marc Belsky: 765,000 options.","CMO Noreen Roth Henig (980,000 options) and Strategic Advisor Christopher Kirk (832,500) included.","Repricing excludes options under the 2015 Plan and 2022 Inducement Plan; all other terms unchanged.","Purpose: retain key contributors and preserve cash without additional equity dilution."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-034761","json":"https://secwatch.observer/filing/0000950170-23-034761.json","markdown":"https://secwatch.observer/filing/0000950170-23-034761.md","text":"https://secwatch.observer/filing/0000950170-23-034761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023034761/0000950170-23-034761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017023034761/kzr-20230724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:22:16.943691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}